Production of Vaccines Using Biological Conjugation

Methods Mol Biol. 2022:2414:281-300. doi: 10.1007/978-1-0716-1900-1_15.

Abstract

The production of conjugate vaccines within an E. coli (Escherichia coli) host provides an inexhaustible supply without the need for culture of pathogenic organisms. The machinery for expression of glycan and acceptor protein, as well as the coupling enzyme, are all housed within the E. coli chassis, meaning that there are no additional steps required for individual purification and chemical conjugation of components. In addition, there are far fewer purification steps necessary to obtain a purified glycoconjugate for use in vaccine testing. Here we describe production and purification of a HIS-tagged Campylobacter jejuni AcrA protein conjugated to Streptococcus pneumoniae serotype 4 capsule.

Keywords: Biological conjugation; PGCT; PglB; Streptococcus pneumoniae; Vaccine.

MeSH terms

  • Campylobacter jejuni
  • Escherichia coli / genetics
  • Glycoconjugates
  • Polysaccharides
  • Vaccines, Conjugate*

Substances

  • Glycoconjugates
  • Polysaccharides
  • Vaccines, Conjugate